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Abstract
Effective antiretroviral therapy (ART) blunts viraemia, which enables HIV-1-infected individuals 
to control infection and live long, productive lives. However, HIV-1 infection remains incurable 
owing to the persistence of a viral reservoir that harbours integrated provirus within host cellular 
DNA. This latent infection is unaffected by ART and hidden from the immune system. Recent 
studies have focused on the development of therapies to disrupt latency. These efforts unmasked 
residual viral genomes and highlighted the need to enable the clearance of latently infected cells, 
perhaps via old and new strategies that improve the HIV-1-specific immune response. In this 
Review, we explore new approaches to eradicate established HIV-1 infection and avoid the burden 
of lifelong ART.
HIV-1 infection remains incurable owing to the presence of quiescent, replication-competent 
provirus within a long-lived population of memory T cells, which are capable of reigniting 
new rounds of infection if therapy is interrupted. In adults, this latent pool of virus is 
established within days of infection and is unaffected by the antiviral immune response or 
by current therapy. HIV-1 preferentially infects activated CD4+ T cells, which leads to 
massive depletion of these cells, as well as the accompanying immune suppression and 
exhaustion that are characteristic of HIV-1 infection. Infection begins when the HIV-1 
envelope (Env) engages the CD4 receptor and a CC-chemokine receptor, usually CCR5 and 
rarely CXC-chemokine receptor 4 (CXCR4), on the surface of host cells, which leads to 
fusion of the viral and cellular membranes and thus enables entry of the viral nucleocapsid 
into the cell. The viral RNA genome is reverse transcribed into proviral double-stranded 
cDNA, which together with viral and host cellular proteins forms the pre-integration 
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complex (PIC). This complex is imported into the nucleus, where integration of the proviral 
cDNA into the host genome occurs. In activated T cells, infection proceeds with the 
transcription of viral mRNAs, protein production and the generation of new viral particles. 
In resting T cells, the provirus may enter quiescence, whereby it exists in a latent state as 
part of the host gene in which it is integrated.
Several classes of drugs that target the different stages of the viral life cycle have been 
successfully used in combination antiretroviral therapy (cART) for the treatment of HIV-1 
infection. These include: fusion inhibitors and CCR5 co-receptor antagonists, which block 
viral entry; nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse 
transcriptase inhibitors (NNR-TIs), which block reverse transcription of the viral genome; 
integrase inhibitors, which prevent viral integration; and protease inhibitors, which interfere 
with virion production. However, there are currently no available therapies that target the 
quiescent integrated form of the virus, and unless this persistent latent infection is 
eradicated, HIV-1 will remain a chronic viral infection with the enduring potential to cause 
or spread lethal disease.
Although disappointing, the recent return of viraemia in an infant born to an HIV-1-positive 
mother (known as the ‘Mississippi baby’)1 more than 2 years after the interruption of ART 
suggests that individual latently infected cells may remain dormant for considerable periods 
of time, and perhaps, if the number of latently infected cells is low enough, an antiviral 
immune response may stringently contain infection. HIV-1 rebounded only several months 
after stopping treatment in two patients (known as the ‘Boston patients’) who received bone 
marrow transplants to treat lymphoma2. The shorter time off therapy before rebound in the 
Boston patients might simply reflect a higher number of latently infected cells in the adult 
patients and/or the absence of memory T cells that could harbour quiescent, replication-
competent provirus in the Mississippi baby at birth. Approaches to disrupt latency or 
durably enforce latency, in combination with effective therapeutic agents that continuously 
enhance the immune response to HIV-1 infection, must now be even more seriously 
considered.
In this Review, we briefly describe the main mechanisms that are involved in the 
establishment and maintenance of HIV-1 latency and discuss cellular HIV-1 reservoirs, 
including memory T cells and their precursor cells, as well as myeloid cells, with a focus on 
macrophages. We then discuss the current cell and animal models that are available for the 
study of HIV-1 latency and the proposed strategies to disrupt latent infection and enable 
clearance of persistently infected cells.
HIV-1 latency
Latently infected resting memory CD4+ T cells are the best characterized reservoirs of 
HIV-1 infection. These are a small population of cells that, rather than dying from the direct 
or indirect cytopathic effects that are induced by the virus, persist after infection as long-
lived cells that harbour integrated HIV-1 DNA in their genomes3. This latent reservoir is 
established within days of acute infection4, with continued contributions from active, 
uncontrolled viraemia in the absence of ART, and although early treatment with ART can 
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reduce the size of this pool of infected cells, it cannot prevent the establishment of latent, 
persistent HIV-1 infection5,6.
Infection of resting CD4+ T cells is far less efficient than infection of activated cells7–10, 
which express factors that are crucial for HIV-1 transcription. Latency may primarily be 
established in activated CD4+ T cells that are infected as they transition to the resting 
memory state11. However, recent studies using primary CD4+ T cells that are infected with 
dual-labelled HIV-1 reporter viruses suggest that a small fraction of transcriptionally silent 
infection occurs directly in activated CD4+ T cells that have not yet transitioned to a resting 
state12. Whether this phenomenon occurs in vivo remains to be determined. HIV-1 persists 
in resting cells, but is transcriptionally silent and therefore ‘hidden’ from immune 
surveillance and unaffected by ART4,13. However, as latent HIV-1 still remains replication-
competent and has the ability to re-emerge when therapy is interrupted, it poses a 
considerable barrier to the eradication of HIV-1. Furthermore, there are currently no known 
cellular biomarkers that distinguish latently infected cells from uninfected cells, although it 
has been shown that some latently infected resting CD4+ T cells express high levels of CD2 
(REF. 14).
Despite some evidence to the contrary15,16, ongoing viral replication has been suggested to 
contribute to the persistence of HIV-1 infection even in the presence of therapy. Sensitive 
assays have detected trace levels of viraemia in many ART-treated patients17,18. This 
phenomenon seems to be the result of continuing viral expression from cells that were 
infected before the implementation of ART. However, it has been suggested that ongoing 
viral replication in a pro-inflammatory environment within lymphoid tissue contributes to 
the maintenance of persistent infection. Evidence for ongoing viral replication has 
previously been reported19–21 and cell-to-cell spread of HIV-1 was recently proposed as a 
mechanism that facilitates ongoing replication despite ART22; however, these findings have 
been challenged23–25.
The adequacy of ART is an area of continued controversy. Treatment intensification with 
the integrase inhibitor raltegravir had no effect on low-level viraemia, but it was associated 
with an increase in the generation of circular HIV-1 DNA episomes that contain two copies 
of the two-long terminal repeat circles (2-LTR circles)21,26 and a reduction in the levels of 
recoverable HIV-1 (REF. 27). However, these findings were not seen in all raltegravir 
intensification studies28.
Another recent study observed persistent HIV-1 RNA expression in tissues (although after 
only 6 months of therapy) and low levels of some antiretroviral drugs in some tissues29. 
However, it has been noted that, although intracellular active nucleotide metabolites remain 
stably inside cells during processing30, parent drugs quickly diffuse out of cells31, which 
makes it difficult to obtain accurate measurements of active drug levels. The amount of 
NNRTIs, protease inhibitors or integrase strand transfer inhibitors (INSTIs) that are lost 
from cells during isolation is currently unknown. Furthermore, the fact that low-level plasma 
viraemia remained unaffected following the intensification of therapy and the lack of genetic 
evolution of plasma virus20,32–34,16 leaves many in this field of research convinced that 
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residual viral replication may not be involved in the maintenance of persistent HIV-1 
infection.
Homeostatic proliferation of latently infected cells may alternatively, or additionally, 
contribute to the maintenance of this cell pool35,36. Recent studies have shown an 
enrichment of HIV-1 DNA integrated in, or near to, host genes that are associated with cell 
cycle control. These findings suggest an alternative mechanism for proviral persistence, 
whereby the integration of HIV-1 into such sites could lead to proliferation of the latently 
infected cells37,38. However, further experiments are necessary to fully examine this theory, 
and it is possible that the observed results were reflective of accumulated, defective proviral 
DNA rather than truly replication-competent virus39. Like host gene expression, the latency 
of integrated, proviral DNA is regulated by multiple cellular mechanisms, including 
epigenetic transcriptional silencing, the availability or deficiency of key host factors and 
transcriptional interference (reviewed in detail in REF. 38). Briefly, host transcription 
factors, including nuclear factor-κB (NF-κB), nuclear factor of activated T cells (NFAT), 
AP1 and SP1, are sequestered in the cytoplasm in resting cells and thus do not promote 
HIV-1 transcription until an appropriate cellular activation signal is transmitted (FIG. 1). 
HIV-1 integration into the host genome preferentially occurs within introns of actively 
transcribed host genes40–42. Multiple distinct and complementary mechanisms contribute to 
the establishment of latent proviral infection (FIG. 1).
Epigenetic modifications are involved in the initial establishment and subsequent 
enforcement of transcriptional silencing of the provirus. Independent of the site of 
integration, the viral 5′ LTR is occupied by two specific nucleosomes — Nuc-0 and Nuc-1 
(REF. 43) — that can be marked by repressive post-translational histone modifications44,45. 
Histone deacetylation is associated with transcriptional repression of the HIV-1 promoter, 
and inhibition of histone deacetylases (HDACs) reactivates latent HIV-1 (REF. 46). Histone 
methyltransferases (HMTs), such as EZH2, G9a and SUV39H1, have also been suggested to 
contribute to latency in T cells45,47. These chromatin marks create an environment that 
favours the recruitment of additional factors and complexes that antagonize proviral gene 
expression.
An additional, or complementary, mechanism to suppress the expression of the integrated 
provirus is transcriptional interference, which involves the integration of the provirus in the 
same orientation but down-stream of an actively transcribed host gene (known as promoter 
occlusion) or the integration provirus in the opposite orientation relative to the host gene 
(known as convergent transcription) (FIG. 1). Transcriptional elongation is suppressed by 
sequestration of positive transcription elongation factor b (p-TEFb), which comprises cyclin-
dependent kinase 9 (CDK9) and cyclin T1 (REFS 48,49) and associates with the HEXIM1–
7SK small nuclear RNA (snRNA) regulatory complex. CDK9 is constitutively expressed in 
resting cells in an inactive dephosphorylated form50. HIV-1 Tat recruits p-TEFb to the viral 
promoter, where active CDK9 can promote transcriptional elongation46 (FIG. 1).
Finally, microRNAs (miRNAs) may contribute to latency, although their specific role has 
not yet been fully established (reviewed in REF. 51). The factors and steps that lead to 
complete HIV-1 transcription after reactivation have recently been reviewed46.
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Cellular reservoirs of HIV-1
It is crucial to identify and fully characterize all reservoirs of persistent HIV-1 infection so 
that specific therapies can be devised. The nature of these reservoirs is still a subject of 
controversy. To meet the criteria of a long-lived, latent reservoir of HIV-1 infection, an 
infected cell population must persist for months, restrict viral expression to the extent that 
viral antigen is not presented and harbour quiescent virus that is replication-competent 
following reactivation.
Memory CD4+ T cells
HIV-1 DNA is primarily detected in two subsets of memory CD4+ T cells: central memory 
CD4+ T cells (TCM cells) and transitional memory CD4+ T cells (TTM cells)35. TTM cells are 
characterized by the expression of CD27 but lack expression of the lymph node homing 
receptor CCR7, whereas TCM CD4+ T cells express both CD27 and CCR7. The frequency of 
infection of TCM cells is associated with the presence of human leukocyte antigen-B27 
(HLA-B27) and HLA-B57, which have been shown to have a protective role in long-term 
non-progressors52.
Interleukin-7 (IL-7)-mediated homeostatic proliferation was reported to be the main 
mechanism that maintains latency in TTM cells in patients with low CD4 counts, whereas 
antigen-driven T cell receptor (TCR) activation maintains the reservoir in TCM cells35, 
although in this case the hypothesis holds that antigen-driven activation must not be 
sufficiently strong to induce reactivation of HIV-1 from these cells36. Another recent study 
found that HIV-1 DNA and RNA levels were high among TTM cells in patients who are 
early in the course of infection53. However, preliminary analysis of the frequency of 
replication-competent virus by a quantitative viral outgrowth assay (QVOA) (BOX 1) in 
TCM and TTM cells showed that TTM cells are major contributors to the HIV-1 reservoir in 
only a minority of the patients studied, and in those patients, infection of TTM cells does not 
seem to persist as it does in TCM cells54,187. Owing to the challenges that are inherent in 
comparing measurements of rare events in small populations of cells, further longitudinal 
analyses are needed to clarify whether TTM cells constitute a durable and clinically 
significant reservoir in patients who are successfully treated with ART and who have normal 
CD4 counts.
Box 1
Assays of persistent infection
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The quantitative viral outgrowth assay (QVOA)174,175 measures rare replication-
competent but latent HIV-1 (see the figure, part a). Highly purified latently infected 
resting CD4+ T cells are plated in a serial dilution and are maximally activated to reverse 
latency. Activated peripheral blood mononuclear cells (PBMCs) that are isolated from 
uninfected donors are added to propagate the virus. The QVOA is costly, slow and 
unavoidably requires many cells. Further, it may under-represent the true frequency of 
latent infection, as some ‘non-induced’ proviruses are not recovered following the single 
stimulation that is used in this assay138. Improvements to the QVOA are being sought, 
but it currently remains the most reproducible and reliable method to measure HIV-1 
latency and assess eradication strategies176.
Quantitative PCR (qPCR) measures total or integrated HIV-1 DNA, or cell-associated 
RNA (caRNA), in cells and is the most commonly used method to quantify persistent 
HIV-1 infection177. Two-long terminal repeat (2-LTR) circles may be a marker for low-
level replication in patients on antiretroviral therapy (ART), but this is controversial177. 
The caRNA may be a useful measure of residual virus expression or of the frequency of 
latent infection178. As caRNA indiscriminately measures functional, defective or abortive 
viral RNA, levels of caRNA in patients treated with ART may not reliably correlate with 
the frequency of replication-competent HIV-1 (REF. 178). Nevertheless, changes in 
caRNA levels can enable the assessment of anti-latency interventions in vivo130,132,133.
Single-copy assays of plasma HIV-1 RNA, which are an ultrasensitive, well-established 
method to quantify low-level plasma viraemia in patients receiving ART, might 
contribute to monitoring eradication therapies179. Droplet digital PCR (ddPCR) (see the 
figure, part b) is under development to improve assay precision for low levels of HIV-1 
DNA and caRNA180–182. The droplet technique enables the sample and PCR reaction 
mixture to be partitioned into thousands of individual droplets such that each contains a 
single copy of the target, which facilitates precise endpoint quantification.
However, PCR-based assays cannot distinguish defective proviruses from intact 
ones183,184. HIV-1 DNA forms are detected about 300-fold more often than replication-
competent HIV-1 in QVOAs185. ELISA, enzyme-linked immunosorbent assay; PHA, 
phytohaemagglutinin.
Other T cell subsets
In addition to the well-established memory CD4+ T cell reservoir, it is possible that less 
differentiated populations of CD4+ T cells function as long-term, cellular reservoirs. The 
role of CD34+ haematopoietic progenitors as additional reservoirs for HIV-1 has been 
controversial for many years55; for example, HIV-1 infection and the establishment of latent 
infection in CD34+ haematopoietic progenitor cells in patients on ART have been 
reported56,57, but these studies were not confirmed by others58,59. If progenitor cells are 
durably latently infected, they could be a source of persistent HIV-1 production when these 
cells go through proliferative cycles. However, the initial description of HIV-1 infection in 
these haematopoietic stem and progenitor cells found that proliferation resulted in the death 
of these infected cells in vitro56,57. Therefore, although this reservoir might be established 
before therapy, it would be expected to decay over time during treatment.
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In addition to memory CD4+ T cells, latent infection of naive CD4+ T cells in patients on 
ART has also been shown, although this event seems to occur with even lower 
frequency35,60. A recent study reported that CD4+ memory stem cells (TSCM cells) 
constitute a novel HIV-1 reservoir that may not be large but that seems to be stable over 
time61. TSCM cells are a population with characteristics of stem cells: they have a less 
differentiated phenotype and are reported to be extremely long-lived62,63. The contribution 
of these TSCM cells to the total HIV-1 reservoir, which is reported to be less than 10%, may 
be especially relevant in patients with small TCM cell reservoirs.
Preliminary work also detected the presence of replication-competent virus and HIV-1 DNA 
in γδ T cells, which are a subset of CD3+ T lymphocytes that harbour alternative TCRs 
formed by γ-chains and δ-chains54. The biology of γδ T cells differs from conventional αβ T 
cells; for example, γδ T cells do not recognize peptide antigens but rather recognize lipid 
antigens in a major histocompatibility complex (MHC)-unrestricted manner64–68. These 
differences in the signalling and activation of γδ T cells suggests the induction of latent 
HIV-1 provirus in γδ T cells may have different requirements.
Persistent infection of macrophages
Enduring infection of macrophages, their precursors or other myeloid lineage cells, such as 
dendritic cells, has long been a concern. Infection of macrophages, with the potential for 
both high-level viral production in the presence of macrophage-derived pro-inflammatory 
cytokines, and the potential for durable viral production, given the resistance of 
macrophages to viral cytopathicity in vitro, was first demonstrated nearly 30 years ago69–71. 
HIV-1 has been recovered from the circulating monocyte pool of patients treated with 
ART72, but the durability of this reservoir has not been carefully measured as it has in 
memory T cells. Brain astrocytes, microglia and other related cellular lineages in the brain 
have been shown to support a restricted infection that could persist despite ART73,74. 
However, even after years of study, a clear demonstration that macrophages and these other 
related cells are truly latent viral reservoirs is lacking. Such cells have not fulfilled the strict 
definition of latency, which is the recovery of cells from a patient or animal on durable, 
suppressive ART that produce virions only following activation.
However, although definitive proof is lacking, several characteristics of these cell types 
would seem to make them ideal reservoirs for long-term infection. The long-standing view 
of macrophages as terminal cells in the myeloid differentiation pathway has recently 
changed, and the ability of macrophages to self-renew and repopulate tissues has been 
appreciated75. This presents the possibility that, like T cells, infected macrophage 
populations could persist despite low-level virion production and clearance of some infected 
cells, if at least one-half of the dividing macrophages escaped viral cytolysis. It is crucial to 
be clear about the difference in persistence of HIV-1 infection in myeloid cells — in which 
cells may survive for long periods of time while viral genomes are in a state of non-latency 
and low-level HIV-1 expression — and true virological latency in CD4+ T cells — in which 
the viral genomes must be mostly silenced, without any appreciable expression of viral 
proteins. This distinction results in key differences in methods to detect persistent infection 
in myeloid cells and to eliminate persistent infection (BOX 1); for example, the challenge of 
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disrupting latent infection in CD4+ T cells may be of little relevance in macrophages if 
productive infection already persists owing to very low-level viral expression. If this is the 
case, we would instead need to develop interventions to assist in the clearance of persistently 
infected myeloid cells.
Recent advances in the implementation of fully effective ART in the non-human primate 
(NHP) SIV model system (see below) offer hope that this controversy will soon be 
resolved76, as extensive and conclusive tissue sampling of optimally treated animals should 
be possible. In addition, recently developed humanized mouse models of latent HIV-1 
infection will address this question in the context of the human virus in human cells77. The 
flexibility of the humanized BLT (bone marrow–liver–thymus) mouse has recently enabled 
the generation of animals that have macrophages but that do not have T cells78. If infection 
persists in this model system in the presence of continuous therapy, this would provide 
definitive proof of a latent reservoir in macrophages.
Model systems of HIV-1 latency
No model can fully recapitulate the complexities of the latent reservoir in vivo. However, as 
clinical trials will always necessarily limit therapeutic interventions to those with reasonable 
expectations of safety and efficacy, models will continue to have a crucial role in HIV-1 
eradication research (FIG. 2).
Cell models of latency
Cell models have been particularly useful for understanding the basic mechanisms that are 
involved in establishing and maintaining latency as well as for the initial screening of 
latency-reactivating agents79 (FIG. 2a–c). Although resting memory CD4+ T cells constitute 
the major latent HIV-1 reservoir in humans, studies using these cells are limited by the very 
low frequency of infection80. Primary cell models aim to overcome these limitations by 
establishing latent HIV-1 infection in CD4+ T cells that have been isolated from HIV-1-
negative donors at a higher frequency. As such cells are not immortalized or clonal, primary 
cell models might offer a more physiologically relevant representation of latency than cell 
lines, and their responsiveness to stimuli might be more representative of in vivo biology. 
Several cell models are currently being used81–88 (reviewed in REFS 89,90), and there are 
important differences in the cell subsets, viral strains and mechanisms that are used to 
establish latency89,90 (TABLE 1). A careful comparison of latent HIV-1 reactivation by 
different stimuli across multiple primary cell models revealed diverse responses to the same 
stimuli. In addition, such responses are not uniformly consistent with results obtained using 
QVOA in resting CD4+ T cells that have been isolated from aviraemic patients infected with 
HIV-1 (REF. 89) (BOX 1). For example, HIV-1 expression can be induced in J-lat clones 
and primary cells from patients by HDAC inhibitors, whereas several primary cell models of 
latency are resistant to the effects of HDAC inhibitors. Given the complexity and diversity 
of latency in vivo and the varying responses of these models, information from primary cell 
models may be expanded by evaluating responses in more than one model91.
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The establishment of successful mouse models of latent HIV-1 infection required substantial 
adaptation of the host (FIG. 2d,e), as mice are not naturally susceptible to HIV-1 infection 
(reviewed in REF. 92). The development of the humanized BLT mouse77,93–97, which is 
characterized by a complete reconstitution of human immune cells, including full mucosal 
immunity, has greatly increased the ability to study the distribution of infection and 
latency77,96,98–102 (FIG. 2e). A recent study102 extensively characterized sites of residual 
active viraemia during ART in blood and multiple tissues and found reduced, but detectable, 
residual viral RNA expression in all tissues (especially lymphoid tissues), despite adequate 
tissue drug concentrations. The humanized BLT mouse model also enables manipulation of 
the immune system to generate HIV-1-resistant cells and/or an enhanced immune response 
via transgenic or short hairpin-mediated modifications of CD34+ stem cells before 
transplantation103,104. Further adaptations of humanized mice that are aimed at isolating 
discrete cell populations of interest are currently being developed; for example, using a 
novel T cell-only humanized mouse model105, a recent study showed that latency is 
established in resting CD4+ T cells despite the absence of monocytes, macrophages, B cells 
and dendritic cells.
NHP models
Animal models are well-suited for the study of the anatomical and cellular distribution of 
latent infection in the setting of ART treatment, as well as for the evaluation of certain high-
risk treatments that would be unethical for initial human trials (FIG. 2f). SIV and 
recombinant viral strains derived from SIV (such as RT-SHIV and SHIV) cause a 
pathogenic disease course in Asian macaques that is similar to that of HIV-1 in humans, and 
treatment with ART results in plasma viral decay106–110 and the establishment of inducible 
replication-competent virus in resting CD4+ T cells106,111. Neurotropic strains of SIV, such 
as SIV/17E-Fr, have also been used to establish models of central nervous system (CNS) 
disease during infection and ART107,112–114. These studies have shown the establishment of 
HIV-1 DNA early in the course of infection, despite the initiation of ART during acute 
infection, although the specific cellular reservoirs within the brain tissue were not delineated 
and studies were limited by reliance on evaluation of HIV-1 DNA rather than replication-
competent virus. The development and application of recombinant RT-SHIV115 has 
provided further approaches to characterize latent reservoirs following treatment with 
clinically relevant ART regimens116,117. RT-SHIV-infected macaques that were treated with 
ART were found to have a widespread distribution of both viral RNA and DNA, especially 
in the gut and lymphoid tissues116.
The SIV–macaque model was also key to understanding the role of the immune response in 
controlling HIV-1 infection118. Recent studies using a rhesus cytomegalovirus (CMV) 
vector vaccine in macaques, followed by infection with SIV, led to suppression of viraemia 
below the limit of detection in 50% of animals119,120. Although correlates and mechanisms 
of protection are still under investigation, interestingly, the rhesus CMV vector induced a 
non-canonical, MHC II-restricted CD8+ T cell response. It is unclear how directly 
translatable the magnitude of the results will be in human trials, especially for patients who 
started ART during chronic therapy. Autologous pre-infected CD34+ haematopoietic stem 
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cell (HSC) transplants have also been used in SIV-infected macaques as a tool to investigate 
the potential contribution of non-haematopoietic reservoirs to the persistence of HIV-1 
(REF. 121). In addition, transplantation of autologous HSCs that were genetically 
engineered to be HIV-1-resistant has also been explored as a therapeutic strategy in 
macaques122. However, although similar to humans, the macaque immune response to SIV 
is distinct, and results that are obtained in macaques might not translate to the human 
system.
Strategies to disrupt latent infection
Several modalities to target the latent reservoir have been proposed. These interventions aim 
at inducing proviral expression to enable clearance of the virus and infected cells123 (FIG. 1; 
TABLE 2). Early attempts to reactivate virus production via global T cell activation using 
OKT3 and IL-2 in combination led to toxic levels of immune activation, and thus current 
strategies focus on reactivating the virus in the absence of T cell activation124. However, 
most of these approaches have been validated only in cell line models of HIV-1 latency, and 
only a few have been tested in resting CD4+ T cells that have been isolated from aviraemic 
patients51,91,125–128.
Many primary cell models of latency have recently been developed, and the responses of 
these models to a panel of reagents that are known to induce LTR expression were compared 
in a comprehensive study89. Although some of these models reflect the responses that have 
been obtained in resting CD4+ T cells that have been isolated from aviraemic patients, none 
precisely reflects the responses of cells from patients to every type of anti-latency modality 
that has been tested89. Furthermore, a recent report using resting CD4+ T cells from 
aviraemic patients showed that latency-reversing agents, such as HDAC inhibitors, only 
weakly induced HIV-1 transcription129, but it is difficult to directly compare the precise 
assays and conditions that were used in this study to those measured in a clinical trial130. 
Therefore, in primary polyclonal cell models of HIV-1 latency, cell-specific factors present 
a challenge to the use of ex vivo cell systems for the validation of potential anti-latency 
approaches, and even the research assays that are used to evaluate cells from patients still 
lack a relevant clinical endpoint (that is, depletion of latent infection) to validate the 
relevance of the effects measured.
Nevertheless, the use of small-molecule inhibitors that target HDACs and induce 
transcription at the HIV-1 LTR remains the most well-characterized strategy to purge latent 
HIV-1 (REF. 131), and several HDAC inhibitors have advanced into clinical trials132–134 
(TABLE 2). A single 400 mg dose of the class I HDAC inhibitor vorinostat, can disrupt 
latency in humans, as measured by the expression of HIV-1 RNA in isolated resting CD4+ T 
cells130. The finding of increased levels of HIV-1 RNA transcription on the first day of 
therapy has been replicated in a study in which 14 daily doses of vorinostat were 
administered133 and in another study with the HDAC inhibitor, panobinostat, which was 
administered three times a week for 4 weeks with weekly off-drug intervals132. These 
studies measured HIV-1 RNA in total CD4+ T cells rather than in isolated resting CD4+ T 
cells. In addition, these studies found that, compared with a single baseline pre-dose 
measurement, the levels of unspliced HIV-1 RNA within total CD4+ T cells is increased 
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throughout the dosing period and is still increased 84 days after the initial dose of the HDAC 
inhibitor.
However, a subsequent follow-up study observed a dampened response to vorinostat 
following administration of multiple daily doses to patients who responded to the single 
dose135. Preliminary gene expression analysis of resting CD4+ T cells treated ex vivo with a 
single dose of vorinostat shows a complex multiphasic cascade of host gene expression 
(D.M.M., unpublished observations). Furthermore, dose–response measurements in patients 
who received multiple doses of vorinostat showed an exposure–effect relationship with 
clockwise hysteresis (that is, the response to the initial dose was higher than the response to 
the subsequent doses), which is consistent with tolerance to vorinostat exposure136. Taken 
together, these results suggest that further understanding of the kinetics of the effects of 
vorinostat on a crucial subset of host genes — perhaps those that maintain repression of 
HIV-1 transcription — may be necessary to design a dosing regimen that can lead to 
effective and durable induction of latent HIV-1 genome expression.
Reactivation of HIV-1 expression by itself may not lead to reservoir clearance, and whether 
virion production is necessary to achieve viral clearance has not been proven. It is plausible 
that any viral antigen that is expressed by a latently infected cell that has been stimulated 
may be sufficient for natural killer cell- or cytotoxic T lymphocyte (CTL)-mediated 
clearance137. Clinical trials to test this hypothesis are in the planning stage.
Successful strategies to disrupt latency are likely to include cycles of combination therapy 
that target distinct mechanisms that maintain latency. As shown in recent work138, about 
10% of integrated provirus that does not express detectable HIV-1 RNA following a single 
round of maximal mitogen stimulation may still be fully replication competent, which 
suggests that more than a single round of in vivo T cell stimulation will be required to purge 
the reservoir.
A combinatorial effect of drugs that inhibit HDACs or HMTs, or that induce protein kinase 
C isoforms (to induce NF-κB-mediated LTR transcription), have been described in various 
transformed cell line systems, but how these results will be successfully translated to 
implementation in vivo is unclear139–142. Synergistic combination drug therapy to target 
latent provirus is difficult to define and measure. Synergy of multiple drugs that target 
different mechanisms of latency might induce the expression of a greater proportion of latent 
proviruses or induce expression to a greater extent, which might lead to the death of infected 
cells or improve the recognition and clearance of infected cells by the immune system. 
However, the level of proviral expression that will result in cell death or in immune 
recognition and clearance has yet to be determined. It seems likely that a highly potent 
induction of the latent virus could result in host toxicity and/or levels of viral expression that 
could not be contained by ongoing ART. Synergy has often been described as a combined 
effect that is greater than the sum of the effect of two separate modalities. However, a recent 
study cautioned against this simplistic definition of synergy, given the complexity of 
biological systems, and suggested the use of the Chou–Talalay method143 to more 
accurately measure the effects of multiple antiretroviral drug therapy.
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cART suppresses plasma viraemia and controls HIV-1 infection by targeting specific viral 
enzymes and inhibiting fusion and entry, which enabled the development of well-established 
laboratory models that predict clinical effects. Combination cancer chemotherapy and 
immunotherapy have only recently been successfully used after many years of intense 
research. Lessons from both fields may offer insights into how to proceed with 
combinatorial latency eradication approaches.
An important area for future study is to establish validated cell and animal model systems 
that can reliably evaluate combinatorial approaches to disrupt HIV-1 latency. An initial 
study in the humanized mouse model that examined the effect of a novel immunotoxin that 
recognized and killed cells expressing HIV-1 Env when added to an antiretroviral drug 
regimen has recently been reported102, but the impact of interventions on latent persistent 
infection has not yet been successfully tested in this model or in NHPs. Many questions 
arise in such investigations, such as: which response parameters are predictive of disruption 
of latency in vivo; what is the temporal manner in which reagents are delivered, in series or 
in parallel, in what order and for what duration; do these reagents access all the relevant 
tissue compartments in which latently infected cells reside; do these reagents induce 
clearance without other interventions; if interventions work via a host cell response (for 
example, vaccines, antibodies or cytokines; see below), do host-targeted anti-latency 
therapies affect such adjunctive therapies?
Clearing persistently infected cells
The induction of latent proviral expression may not be sufficient to clear latently infected 
cells by viral cytopathic effects alone144, but the expression of HIV-1 antigens may enable 
the immune system to identify latently infected cells. However, continuous antigenic 
stimulation during HIV-1 infection leads to chronic immune activation and immune 
exhaustion, and therefore HIV-1-specific effector cells are depleted or dysfunctional as they 
lose antiviral function and proliferative capacity145. An effective eradication strategy is 
likely to require interventions to improve the HIV-1-specific immune response (FIG. 3).
Therapeutic vaccines
HIV-1 infection compromises T cell effector function and also provokes B cell exhaustion, 
which may result in an inadequate antibody response146. The objective of a therapeutic 
vaccine is to enhance the immune response against infection using a controlled in vivo 
exposure to HIV-1 antigens. The rebound viraemia that was observed in the Mississippi 
baby after 27 months of ART interruption poignantly illustrates the need for a robust, 
durable antiviral immune response that eliminates every single infected cell. Mutations that 
confer resistance to CTLs are prevalent in the latent reservoir147,148 and present a 
formidable but not insurmountable challenge that might be overcome in the setting of a 
small reservoir in which the restriction of viral escape is enforced by ART, by a vaccine that 
targets carefully chosen conserved, autologous or polyclonal epitopes, or by novel strategies.
Several therapeutic HIV-1 vaccines have been tested, including whole inactivated virus, 
recombinant proteins or viruses, DNA vectors or dendritic cell presentation of autologous 
antigens (reviewed in REF. 149) (FIG. 3a). Some vaccines improved HIV-1-specific 
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immune responses150,151, but none so far has enabled sustained interruption of ART, and 
this metric may be inappropriately stringent for the goal of eradication in the setting of 
ongoing ART and anti-latency therapies. Furthermore, such vaccines have not yet been 
tested for the most relevant factors in the context of eradication strategies, such as: the 
recognition of relevant epitopes in the context of infection emerging from the latent state; a 
reduction of low-level viraemia that persists during ART; or a decrease in the frequency of 
latently infected cells. These aspects should be considered in future studies.
Cell-based therapies
One potential strategy to clear persistently infected cells is the adoptive transfer of HIV-1-
specific CTLs152. In a primary cell model of latency, Gag-stimulated CTLs are much more 
effective at clearing reactivated HIV-1-infected cells than freshly isolated CD8+ T cells144. 
Preliminary work shows that expansion of T cells against multiple overlapping peptides 
from different HIV-1 antigens enables increased clearance of reactivated latently infected 
cells ex vivo153.
Other cytotoxic immune cells are of interest owing to their potential to clear infected cells, 
in some cases using mechanisms that complement the action of CTLs154. Natural killer 
cells, lymphokine-activated killer (LAK) cells155 and γδ T cells156 are also very effective at 
eliminating virally infected targets. However, similarly to CTLs, these immune effectors 
require priming for optimal function. In oncology applications, effector cells are primed 
with cytokines, such as IL-15, that have been administered directly in vivo or used ex vivo 
for activation before reinfusion157,158. Monoclonal antibodies could also improve effector 
cell engagement with the infected targets and, in the case of natural killer cells, mediate 
targeted lysis via antibody-dependent cellular cytotoxicity (ADCC)159,160 (FIG. 3b).
Gene therapy
Effector cells can also be genetically engineered to increase their efficiency and redirect 
them to the desired targets. Such approaches have been pioneered in oncology, whereby T 
cells are genetically modified to express chimeric antigen receptors (CARs) with improved 
antigen specificity161. This strategy has been adapted to target HIV-1 by genetically 
modifying peripheral blood cells with a molecularly cloned TCR that redirects cells to viral 
antigens (FIG. 3c). Encouraging results were shown in a study in which a TCR from a 
patient who had a sustained and robust CTL response against the HIV-1 p17 Gag-derived 
antigen SL9 was cloned and expressed in primary CD8+ cells162, and a Phase 1 clinical trial 
is being carried out (clinicaltrials.gov identifier NCT00991224). Nonetheless, this novel and 
promising tool should be carefully explored owing to potential off-target toxicities163. 
Although such approaches might be too resource-intensive to be implemented on a global 
scale, they may provide proof-of-concept that could lead to strategies that are appropriate for 
global implementation.
Reversing immune exhaustion
Chronic HIV-1 infection leads to the upregulation of inhibitory co-receptors, such as PD-1, 
on T cells164 and cytotoxic T lymphocyte-associated protein 4 (CTLA4) (REF. 165), which 
are cellular markers of immune exhaustion91 that have an important role in the ineffective 
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viral immune response. Blockade of the PD-1 pathway reverses this state of exhaustion and 
restores the ability of T cells to inhibit HIV-1 replication in vitro and in vivo in animal 
models166 and thus presents a promising potential therapeutic intervention (FIG. 3a) that 
will soon be tested in a clinical trial (clinicaltrials.gov identifier NCT02028403).
Immunotoxins and radioimmunotherapy
Immunotoxins are bifunctional chimeric proteins that consist of a targeting portion, such as 
an antibody or a ligand, and a toxin effector domain167. Initial clinical trials using 
immunotoxins did not have a sustained impact on immunological or clinical endpoints168, 
perhaps owing to the lack of support from an ART regimen. The addition of the 
immunotoxin 3B3-PE38 (REF. 169) to ongoing ART was recently shown to reduce tissue 
levels of HIV-1 RNA in a humanized mouse model102 to several logs below the levels that 
are seen with ART alone (FIG. 3d). Moreover, radioimmunotherapy using radiolabelled 
antibodies that target the HIV-1 envelope proteins gp120 and gp41 led to a depletion of 
chronically HIV-1-infected cells in a severe combined immunodeficiency–peripheral blood 
lymphocyte (SCID–PBL) mouse model that does not allow viraemia and viral replication170. 
However such short-term animal studies cannot yet address potential off-target effects, such 
as hepatotoxicity, that are seen with older immunotoxins168.
Conclusions
Efforts to develop therapies that could eradicate HIV-1 infection or achieve a durable 
remission of viraemia in the absence of ART have recently accelerated and expanded. 
Although this initial period of renewed effort has been marked by much progress and 
enthusiasm, both the scientific and the patient community must be prepared for the 
prolonged effort that will be required to overcome both the expected and the unforeseen 
challenges ahead. First, and perhaps most daunting, is the need to target latency within 
specific cellular reservoirs to disrupt viral quiescence so that residual infection can be 
cleared (FIG. 4). An alternative strategy would be to permanently repress HIV-1 gene 
expression or to directly destroy the genome. Recent advances with gene-modifying 
technologies such as zinc-finger nucleases, TALENs (transcription activator-like effector 
nucleases) and the CRISPR–Cas (clustered, regularly interspaced short palindromic repeats–
CRISPR-associated proteins) system are exciting171,172. Although these approaches would 
be more elegant, their implementation would require tremendous advances in gene delivery, 
as efficient and effective delivery systems to destroy the viral genomes in rare cells 
throughout the body are not currently available.
The several approaches to disrupt HIV-1 latency by inducing proviral expression seem to be 
promising and might be implemented in the foreseeable future. As reactivation of the latent 
reservoir may be governed by stochastic mechanisms (that is, some latent genomes remain 
silent even in the event of a single round of maximal mitogen stimulation)138, combinatorial 
latency-reversing therapy that is safe enough to enable multiple administrations may be 
needed. Ongoing work aims at designing an effective dosing regimen. Potency must be 
balanced with minimizing toxicity, and the potential impact of any latency-reversing agent 
on the immune system must be carefully considered.
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In addition, a parallel effort must be made to develop immune-based therapies to ensure and 
accelerate the process of viral clearance. This effort should be linked to studies of the 
disruption of latency, as the modalities are likely to be combined. Therefore, given the broad 
efforts to discover reagents that disrupt latency in resting TCM cells as a first step towards 
viral eradication therapies, systems must be developed to study the interactions between 
anti-latency approaches that might be used in combination, as well as the interactions 
between such agents and immunotherapeutic agents that might be used as a potential cure.
The development of approaches to eradicate HIV-1 infection will take time and durable 
investment in research towards this goal. It is possible that therapies that result in the 
depletion of persistent infection and the augmentation of the immune response might lead to 
an intermediate result. Termed by many as a ‘functional cure’, this is a state in which HIV-1 
infection is not cleared but is so tightly controlled by the immune response that the patient is 
no longer infectious and is clinically stable in the absence of ART. If so, to make such an 
investment superior to once-a-day ART (or less with the long-acting therapeutic agents that 
are currently under development), interventions that result in a functional cure would also 
have to spare patients the chronic immune activation that is seen in natural ‘elite controllers’ 
of HIV-1 infection173, with its attendant risks of long-term morbidity, as otherwise life-long 
ART might then be clinically preferable.
The scientific and medical challenges in the effort to eradicate HIV-1 infection are 
formidable and complex. Ultimately, given the scope of the HIV-1 pandemic, strategies to 
eradicate the disease must be implemented globally. However, to move the field forwards, 
early proof-of-concept studies are likely to involve approaches that are not widely feasible; 
for example, bone marrow transplantation or extremely early HIV-1 treatment may never be 
practical, but the successes and failures of these approaches can provide valuable insights. 
Although disappointing, the very recent viral rebound that was observed in the Mississippi 
baby1 after more than 2 years after ART interruption provides valuable clues. Viral rebound 
after such a long period of time without viraemia in the absence of measurable HIV-1-
specific immunity suggests, akin to the Boston patients2, that individual latently infected 
cells may remain virologically dormant for a considerable period of time before generating 
viraemia. The short duration of aviraemia in the Boston patients compared with the longer 
time off therapy in the Mississippi baby case might simply reflect a lower number of latently 
infected cells or some immune protection conferred during initial exposure to HIV-1 in the 
Mississippi baby. Approaches to disrupt latency, or even robustly enforce latency, may 
succeed if the infected cell population is small enough and durable mechanisms to enhance 
the HIV-1 immune response are present.
As efforts advance, additional obstacles to clear HIV-1 infection are likely to be uncovered, 
and careful consideration must be given to the ethics of translational research with otherwise 
healthy volunteers infected with HIV-1. The recent reinvigoration of efforts to gain a 
detailed understanding of the biology and pathogenesis of viral latency should give hope that 
we can overcome these obstacles. The journey towards a cure for HIV/AIDS has begun.
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Glossary
Activated CD4+ T 
cells
Antigen-specific CD4+ T cells that have undergone stimulation of 
their T cell receptor–CD3 complexes. Activation of a T cell 
increases the surface expression of many proteins, including CD69 
and CD25, and induces functional responses, such as proliferation 
and cytokine production
HIV-1 reservoirs Infected cell populations that enable the persistence of replication-
competent HIV-1 in patients treated with antiretroviral therapy 
regimens in the order of years. The HIV-1 reservoir comprises 
both latent HIV-1 infection and other as-yet incompletely defined 
sources of persistent HIV-1
Resting memory 
CD4+ T cells
Antigen-specific CD4+ T cells that have reverted to the G0 state of 
the cell cycle from a previously activated state but retain the 
capability to rapidly respond to a second antigenic exposure
Latent HIV-1 Quiescent, replication-competent provirus that exists within a 
long-lived population of resting cells and that is capable of 
initiating new rounds of infection if therapy is interrupted
Two-long terminal 
repeat circles
(2-LTR circles). The joining of the two ends of the linear 
unintegrated HIV-1 DNA (each end having a complete long 
terminal repeat) into a circularized form of DNA
Homeostatic 
proliferation
A physiological process that controls stable and constant cell 
number without cellular differentiation. Interleukin-7 has a crucial 
role in maintaining normal T cell levels
Central memory 
CD4+ T cells
(TCM cells). Antigen-specific CD4+ T cells that lack immediate 
effector function but that mediate rapid recall responses and have 
the capacity to migrate from the blood to the secondary lymphoid 
organs
Transitional 
memory CD4+ T 
cells
(TTM cells). Antigen-specific T cells that transition to the effector 
memory state and have lost the surface expression of the homing 
receptor CC-chemokine receptor 7 but retain the expression of the 




Human haematopoietic cells that give rise to the myeloid and 
lymphoid lineages and can be identified by the expression of 
CD34, CD150 and CD48, but that lack CD244. These cells 
typically comprise 5% of the total cell population in the bone 
marrow
Archin et al. Page 16













CD4+ memory stem 
cells
(TSCM cells). Antigen-specific T cells with a broadly naive 
phenotype but with high surface expression of CD95 (also known 
as Fas ligand), which is a type II transmembrane protein that is 
expressed at high levels by all memory cells
Chou–Talalay 
method
A method in which a combination index (CI) is used to express 
the synergy of drugs. A CI <1 indicates synergy, a CI=1 suggests 
an additive effect and a CI >1 is indicative of antagonism
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Figure 1. Mechanisms involved in the maintenance of HIV-1 latency and strategies to disrupt 
latency
HIV-1 latency is maintained by several mechanisms. a | Transcription factors (TFs), 
including nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT), are 
sequestered in the cytoplasm, which leads to transcriptional silencing. Bryostatin and 
prostratin induce activation of NF-κB, leading to its translocation to the nucleus where it 
activates HIV-1 transcription. b | The HIV-1 long terminal repeat (LTR) is flanked by the 
Nuc-0 and Nuc-1 nucleosomes that, when latent, can encode repressive post-translational 
histone modifications. Histone deacetylases (HDACs), which are recruited by transcription 
factors (such as YY1 and CBF-1), remove the acetyl groups from chromatin. Histone 
methyltransferases (HMTs), such as SUV39H1, G9a and EZH2, deposit methyl groups onto 
histones. HDACs and HMTs enforce the repressive state. Both HDAC inhibitors and HMT 
inhibitors can induce transcription from quiescent LTR promoters. HIV-1 DNA can also be 
methylated, although recent evidence suggests that DNA methylation is an epiphenomenon 
that does not play a part in HIV-1 latency. Bromodomain-containing (BRD) proteins have a 
complex role in HIV-1 transcription initiation and processivity. Recent evidence suggests 
that BRD2 has a unique role in enforcing HIV-1 latency, and therefore, BRD inhibitors such 
as JQ1 may be of use as latency-reversing agents. c | Transcriptional interference may 
contribute to the regulation of HIV-1 latency. If viral DNA is integrated within an intron of 
an upstream host gene, readthrough of RNA polymerase II (Pol II) displaces key 
transcription factors on the HIV-1 LTR (known as promoter occlusion). Conversely, if the 
viral genome is integrated in the opposite polarity relative to the host gene, host RNA Pol II 
complexes may induce premature termination of HIV-1 transcription (known as convergent 
transcription). d,e | The positive transcription elongation factor b (p-TEFb) complex (which 
comprises CDK9 and cyclin T1 (CycT1)) is sequestered in an inactive ribonucleoprotein 
complex with HEXIM1–7SK small nuclear RNA (snRNA). BRD4 may compete with the 
viral Tat activator for binding to p-TEFb. Hexamethylene bisacetamide (HMBA) releases p-
TEFb from the HEXIM1–7SK snRNA inhibitory complex and the small-molecule inhibitor 
JQ1 may antagonize BRD4, both of which enable induction of latent HIV-1 expression.
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Figure 2. Current model systems to study HIV-1 latency
a–c | Cell models. Cell line models (part a) are derived from immortalized T cell clones (for 
example, from Jurkat-derived cell lines) or promonocyte clones (for example, U1), and they 
have uniformly integrated copies of proviral HIV-1 DNA. By contrast, primary cell models 
(part b) are derived from HIV-1-negative donor CD4+ T cells, and latency is established 
following infection using different protocols. Studies in cells obtained from aviraemic, 
antiretroviral therapy (ART)-treated patients (part c) can be studied ex vivo for their 
response to putative latency-reversing agents and other stimuli. d,e | Humanized mouse 
models. Several humanized mouse models have been developed by engraftment of mice 
with various human tissues. Humanized severe combined immunodeficiency (SCID) mice 
(part d) are generated by transplanting irradiated SCID mice with human thymus and foetal 
liver tissue that develops into a human thymic organoid and supports HIV-1 infection, but 
only within this organoid. As HIV-1 replication is limited to the thymus, latency is only 
established in naive T cells. Engraftment of the human immune system was vastly improved 
with the development of the humanized NSG (NOD SCID gamma) mouse (not shown), 
which is generated by transplanting irradiated NOD/SCID/IL-2Rγ chain knockout mice with 
human CD34+ stem cells. Humanized BLT (bone marrow–liver–thymus) mice are generated 
by implanting human foetal thymus and liver cells into NOD SCID or NSG mice and 
transplantation of human CD34+ stem cells (part e). The reconstitution of the human 
immune system and the systemic modelling of HIV infection and latency is most robust in 
this mouse model. f | Non-human primate models. SIV infection in rhesus and pig-tailed 
macaques is similar to the progression of HIV-1 infection in humans. When susceptible, 
SIV-infected animals respond to ART. However, SIV is not susceptible to non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) and its envelope sequence is functionally 
divergent from that of HIV-1. The recombinant SIV viruses RT-SHIV and SHIV are aimed 
at overcoming these limitations using HIV-1 reverse transcriptase and envelope, 
respectively. RT-SHIV enables the use of clinically relevant ART combinations, and SHIV 
models have wider immunotherapeutic potential and can use both CC-chemokine receptor 5 
(CCR5) and CXC-chemokine receptor 4 (CXCR4) co-receptors. PBMCs, peripheral blood 
mononuclear cells.
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Figure 3. Strategies to eliminate latently infected cells
The induction of latent proviral expression and ensuing viral cytopathic effects may not be 
sufficient to clear latently infected cells. An effective eradication strategy is likely to require 
interventions to enhance the HIV-1-specific immune response. Approaches include in vivo 
administration of molecules that improve immune function and the ex vivo stimulation of 
cells that have been isolated from patients infected with HIV-1. a | In vivo administration of 
cytokines, antibodies, inhibitors of the PD-1 pathway or components of a therapeutic 
vaccine present a promising potential therapeutic intervention for enhancing immune 
responses or reversing immune exhaustion. b | Another potential strategy involves ex vivo 
priming of immune effectors for optimal function. Specific cell populations isolated from 
infected individuals, such as cytotoxic T lymphocytes (CTLs), natural killer cells or γδ T 
cells, are stimulated with cytokines, antibodies or HIV-1 peptides and are subsequently 
reinfused. c | Patient-derived effector cells can also be genetically engineered to increase 
their efficiency and redirect them to the desired targets. Peripheral blood cells that have been 
isolated from patients can be genetically modified with a molecularly cloned T cell receptor 
(TCR) that redirects cells to viral antigens, and T cells can be modified to express chimeric 
antigen receptors (CARs) with improved antigen specificity. d | Immunotoxins that consist 
of a targeting portion, such as an antibody or a ligand, and a toxin effector domain can be 
administered in vivo for targeted killing of virally infected cells. Radiolabelled antibodies 
that target HIV-1 proteins could deplete chronically HIV-1-infected cells. ADCC, antibody-
dependent cellular cytotoxicity.
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Figure 4. Barriers to HIV-1 eradication
The frequency of latently infected, resting central memory CD4+ T cells is stable in patients 
despite years of antiretroviral therapy (ART). Therefore, the rate of creation of these cells 
must closely match their rate of destruction. Although the frequency of such infected cells is 
proportional to the exposure to viraemia over time during initial, acute infection, the 
initiation of ART seems to completely block the generation of latently infected cells via new 
infection. As low-level viraemia seems to originate, at least in part, from the expression of 
virus within the latently infected central memory CD4+ T cell pool33,186, this latent reservoir 
must be maintained by one or more mechanisms, such as: new infection at extremely low 
frequency; the ability of some cells to resist death or clearance despite virion production; or 
the homeostatic or aberrant proliferation of a proportion of the cell pool without virion 
production and/or cell clearance.
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Table 2
Ongoing or recently completed clinical trials to disrupt HIV-1 latency
Mechanism to 
disrupt latency
Compound Clinical trials* Comments
PTEN inhibitor Disulfiram Short-term disulfiram administration to accelerate 
the decay of the HIV-1 reservoir in antiretroviral-
treated HIV-1 infected individuals 
(NCT01286259)
Completed: a transient increase in 
single-copy assay viraemia was 
observed in six patients at different 
times after disulfiram dosing; however, 
the size of the HIV-1 latent reservoir 
remained unaffected123
HDAC inhibitor Romidepsin Evaluating the safety and efficacy of single-dose 
romidepsin in combination with antiretroviral 
therapy in HIV-1-infected adults with suppressed 
viral load (NCT01933594)
Enrolling
HDAC inhibitor Romidepsin Safety and efficacy of romidepsin and the 
therapeutic vaccine vacc-4x for reduction of the 
latent HIV-1 reservoir (REDUC; NCT02092116)
Ongoing
HDAC inhibitor Panobinostat (Novartis) Safety and effect of panobinostat on HIV-1 
expression in patients on suppressive HAART 
(CLEAR; NCT01680094)
Completed: a 2.1–14.4-fold increase in 
cell-associated RNA was observed in all 
patients and remained increased 4 
weeks after panobinostat 
administration; however, no change in 
integrated HIV-1 DNA was observed132
HDAC inhibitor Vorinostat The effect of vorinostat on HIV-1 RNA 
expression in resting CD4+ T cells of HIV-1-
infected patients on stable ART (NCT01319383)
Enrolling
HDAC inhibitor Vorinostat A pilot study to assess the safety and effect of 
vorinostat on HIV-1 transcription in patients 
receiving suppressive combination anti-retroviral 
therapy (NCT01365065)
Completed: a significant increase in 
cell-associated RNA was observed in 
88% of patients during vorinostat 
dosing; no significant change in DNA 
was observed133
*
The clinicaltrials.gov identifier is given in brackets.
ART, antiretroviral therapy; HAART, highly active ART; HDAC, histone deacetylase; PTEN, phosphatase and tensin homologue.
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